The compound is made available for research and analytical use only and is not intended for use in humans or for therapeutic, diagnostic or consumer purposes
This interesting finding, occurring without weight loss, is consistent with preclinical and clinical studies showing weight-independent effects of GLP-1R agonism on liver steatosis 51,52,53
In addition, depressed patients who have never been treated may have defective inflammatory pathways in their monocytes, which may be linked to poor responses to treatment
In this context, it has been demonstrated that treatments with either a GLP1/Estrogen (GLP1/E) conjugate, a unimolecular GLP1/GIP (gastric inhibitory peptide) dual agonist, or a GLP1/GIP/Glucagon triagonist, markedly reduced body weight and improved diabetic complications, including hyperinsulinemia, in preclinical models of obesity in males 33,34,35